Suppr超能文献

1型人类免疫缺陷病毒(HIV-1)和2型人类免疫缺陷病毒(HIV-2)感染的塞内加尔患者的异源中和抗体反应比较:广度和强度的不同模式区分HIV-1和HIV-2感染。

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

作者信息

Rodriguez Shaun K, Sarr Abdoulaye Dieng, MacNeil Adam, Thakore-Meloni Seema, Gueye-Ndiaye Aissatou, Traoré Ibrahima, Dia Mamadou C, Mboup Souleymane, Kanki Phyllis J

机构信息

Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA.

出版信息

J Virol. 2007 May;81(10):5331-8. doi: 10.1128/JVI.02789-06. Epub 2007 Feb 14.

Abstract

Neutralizing antibody responses against heterologous isolates in human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections were compared, and their relationships with established clinical markers of progression were examined. Neutralizing responses against 7 heterologous primary isolates and 1 laboratory strain were compared between 32 untreated HIV-1-infected subjects and 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay. The breadth of the neutralizing response, defined as the proportion of panel viruses positively neutralized by patient plasma, was significantly greater among HIV-2-infected subjects than among HIV-1-infected subjects. Notably, for fully one-third of HIV-2 subjects, all viruses were effectively neutralized in our panel. Magnitudes of responses, defined as reciprocal 50% inhibitory concentration (IC(50)) titers for positive reactions, were significantly greater among HIV-1-infected subjects than among HIV-2-infected subjects. When plasma samples from HIV-1 patients were tested for cross-neutralization of HIV-2 and vice versa, we found that these intertype responses are very rare and their prevalences comparable in both HIV-1 and HIV-2 infection. The significantly higher magnitude of heterologous responses for HIV-1 compared to HIV-2 prompted us to examine associations with viremia, which is known to be significantly higher in HIV-1 infection. Importantly, there was a significant positive correlation between the IC(50) titer and viral load within both the HIV-1 and HIV-2 groups, suggesting heterologous antibodies may be driven by viral replication. We conclude that HIV-2 infection is characterized by a broad, low-magnitude intratype neutralization response, while HIV-1 is characterized by a narrower but higher-magnitude intratype response and that a significant positive association between the IC(50) titer and viremia is common to both HIV-1 and HIV-2 infections.

摘要

比较了人类免疫缺陷病毒1型(HIV-1)和HIV-2感染中针对异源分离株的中和抗体反应,并研究了它们与既定疾病进展临床标志物之间的关系。使用假型报告病毒检测法,比较了32名未经治疗的HIV-1感染受试者和35名未经治疗的HIV-2感染受试者针对7种异源原代分离株和1种实验室毒株的中和反应。中和反应的广度定义为患者血浆阳性中和的一组病毒的比例,HIV-2感染受试者中的中和反应广度显著大于HIV-1感染受试者。值得注意的是,在我们的一组病毒中,整整三分之一的HIV-2受试者的所有病毒都被有效中和。反应强度定义为阳性反应的倒数50%抑制浓度(IC(50))滴度,HIV-1感染受试者中的反应强度显著大于HIV-2感染受试者。当检测HIV-1患者血浆样本对HIV-2的交叉中和作用以及反之亦然时,我们发现这些不同类型间的反应非常罕见,并且在HIV-1和HIV-2感染中的发生率相当。与HIV-2相比,HIV-1的异源反应强度显著更高,这促使我们研究其与病毒血症的关联,已知HIV-1感染中的病毒血症显著更高。重要的是,HIV-1组和HIV-2组中IC(50)滴度与病毒载量之间均存在显著正相关,表明异源抗体可能由病毒复制驱动。我们得出结论,HIV-2感染的特征是广泛、低强度的同型中和反应,而HIV-1的特征是较窄但高强度的同型反应,并且IC(50)滴度与病毒血症之间的显著正相关在HIV-1和HIV-2感染中均常见。

相似文献

5
Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.
J Virol. 2012 Jan;86(2):961-71. doi: 10.1128/JVI.06315-11. Epub 2011 Nov 9.
10
Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.
AIDS Res Hum Retroviruses. 2013 Mar;29(3):470-8. doi: 10.1089/AID.2012.0219. Epub 2012 Nov 21.

引用本文的文献

1
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs.
Int J Mol Sci. 2022 Apr 26;23(9):4766. doi: 10.3390/ijms23094766.
2
Novel assays to investigate the mechanisms of latent infection with HIV-2.
PLoS One. 2022 Apr 27;17(4):e0267402. doi: 10.1371/journal.pone.0267402. eCollection 2022.
3
HIV-2 as a model to identify a functional HIV cure.
AIDS Res Ther. 2019 Sep 5;16(1):24. doi: 10.1186/s12981-019-0239-x.
4
Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Front Immunol. 2018 Dec 17;9:2841. doi: 10.3389/fimmu.2018.02841. eCollection 2018.
5
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.
Hum Vaccin Immunother. 2018;14(9):2116-2127. doi: 10.1080/21645515.2018.1462640. Epub 2018 May 24.
6
HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.
EBioMedicine. 2017 Jul;21:158-169. doi: 10.1016/j.ebiom.2017.05.029. Epub 2017 May 31.
7
Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.
J Virus Erad. 2017 Jan 1;3(1):7-14. doi: 10.1016/S2055-6640(20)30300-9.
8
Engineering broadly neutralizing antibodies for HIV prevention and therapy.
Adv Drug Deliv Rev. 2016 Aug 1;103:157-173. doi: 10.1016/j.addr.2016.01.013. Epub 2016 Jan 29.
9
HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.
Retrovirology. 2015 Jan 13;12:2. doi: 10.1186/s12977-014-0131-7.
10
An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.
J Gen Virol. 2015 Mar;96(Pt 3):671-680. doi: 10.1099/vir.0.071522-0. Epub 2014 Nov 13.

本文引用的文献

5
Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
J Exp Med. 2005 May 2;201(9):1407-19. doi: 10.1084/jem.20042510.
6
Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.
J Virol. 2004 Nov;78(22):12455-61. doi: 10.1128/JVI.78.22.12455-12461.2004.
7
Development of the antibody response in acute HIV-1 infection.
AIDS. 2004 Feb 20;18(3):371-81. doi: 10.1097/00002030-200402200-00002.
8
Role of neutralizing antibodies in HIV infection.
AIDS. 2003;17 Suppl 4:S67-71. doi: 10.1097/00002030-200317004-00008.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验